Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Jasper Therapeutics Inc JSPR

Healthcare Biotechnology
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:JSPR)

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

GlobeNewswire March 1, 2025

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

GlobeNewswire February 28, 2025

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire February 27, 2025

Jasper Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire February 25, 2025

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

GlobeNewswire February 10, 2025

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

GlobeNewswire February 4, 2025

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

GlobeNewswire January 8, 2025

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

GlobeNewswire January 6, 2025

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

GlobeNewswire December 2, 2024
View More News ››

Opinion & Analysis (NDAQ:JSPR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:JSPR)

How to Take Advantage of moves in (JSPR)

Just In: $JSPR How to Take Advantage of moves in (JSPR)2025-01-30 03:52:00 ET Stock Traders Daily has produced this trading report using...
whytestocks - January 30, 2025

Trading (JSPR) With Integrated Risk Controls

Breaking News: $JSPR Trading (JSPR) With Integrated Risk Controls2025-01-09 00:10:00 ET Stock Traders Daily has produced this trading...
whytestocks - January 9, 2025

Jasper Therapeutics Reports Positive Data from BEACON Study

JUST IN: $JSPR Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous UrticariaRapid onset of...
whytestocks - January 8, 2025

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Stu

JUST IN: $JSPR Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria14 of 15...
whytestocks - October 14, 2024

Jasper Therapeutics Presents Data from Preclinical Briquilim

NEWS: $JSPR Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid CongressREDWOOD CITY, Calif...
whytestocks - June 14, 2024

Jasper Therapeutics to Present at the Oppenheimer 34th Annua

JUST IN: $JSPR Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference | BenzingaREDWOOD CITY, Calif., Feb...
whytestocks - February 7, 2024
View more Bullboard ››

Xcyte Digital Corp.

Xcyte Digital Corp.

Xcyte Digital is a virtual event company focused on simplifying the event hosting industry and expanding event hosting ...
View More »